Salim Syed
Stock Analyst at Mizuho
(2.40)
# 2,486
Out of 5,157 analysts
78
Total ratings
43.55%
Success rate
1.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MAZE Maze Therapeutics | Initiates: Outperform | $97 | $50.44 | +92.31% | 1 | Mar 10, 2026 | |
| INCY Incyte | Upgrades: Outperform | $90 → $121 | $94.66 | +27.83% | 1 | Dec 8, 2025 | |
| ASMB Assembly Biosciences | Maintains: Outperform | $29 → $40 | $29.21 | +36.94% | 2 | Nov 20, 2025 | |
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $2.43 | +476.13% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $63.63 | +32.01% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $190.48 | -11.28% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $377.64 | -25.86% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $146.00 | -19.86% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $14.08 | +56.25% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $57.53 | +183.33% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $25 → $18 | $6.23 | +188.92% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $30.70 | +10.75% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $99 | $49.93 | +98.28% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $71.39 | -25.76% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.78 | +1,079.78% | 5 | Nov 16, 2022 |
Maze Therapeutics
Mar 10, 2026
Initiates: Outperform
Price Target: $97
Current: $50.44
Upside: +92.31%
Incyte
Dec 8, 2025
Upgrades: Outperform
Price Target: $90 → $121
Current: $94.66
Upside: +27.83%
Assembly Biosciences
Nov 20, 2025
Maintains: Outperform
Price Target: $29 → $40
Current: $29.21
Upside: +36.94%
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $2.43
Upside: +476.13%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $63.63
Upside: +32.01%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $190.48
Upside: -11.28%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $377.64
Upside: -25.86%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $146.00
Upside: -19.86%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $14.08
Upside: +56.25%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $57.53
Upside: +183.33%
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $6.23
Upside: +188.92%
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $30.70
Upside: +10.75%
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $49.93
Upside: +98.28%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $71.39
Upside: -25.76%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.78
Upside: +1,079.78%